RxDoctor Payments Data

Leonid Kleynberg, MD

Hematology & Oncology · Los Angeles, CANPI 1891750212

Payments from drug & device makers

$12,398in general payments, 2019–2025

Across 600 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • Incyte Corporation$1K
  • Johnson & Johnson$1K
  • Amgen$765
  • Pfizer$736
  • AstraZeneca$606
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$12,32399%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.78$1,617
Incyte Corporation67$1,331
Johnson & Johnson(2 entities)73$1,301
Amgen30$765
Pfizer45$736
AstraZeneca(2 entities)31$606
Merck25$498
Bayer18$387
Eisai Inc.16$326
Novartis16$300
Sanofi11$241
Spectrum Pharmaceuticals Inc.9$235
Gilead(2 entities)10$220
CTI Biopharma Corp.6$208
Puma Biotechnology, Inc.9$206
Bristol Myers Squibb8$194
Jazz Pharmaceuticals Inc.8$171
Karyopharm Therapeutics Inc.5$164
Tersera Therapeutics LLC7$156
Seagen Inc.6$155
Genentech USA, Inc.7$148
Daiichi Sankyo Inc.6$133
Sobi, Inc5$124
GSK5$124
Takeda Pharmaceuticals U.S.A., Inc.5$119
Pharmaessentia USA Corporation5$111
Ipsen Biopharmaceuticals, Inc4$102
GE HealthCare4$96
Octapharma USA, Inc.4$96
Dova Pharmaceuticals5$87
Stemline Therapeutics Inc.4$86
ADC Therapeutics America, Inc.3$79
Lilly USA, LLC3$73
Shionogi Inc4$73
Genmab U.S., Inc.3$73
Teva Pharmaceuticals USA, Inc.4$71
Global Blood Therapeutics, Inc.3$61
Mylan Institutional Inc.3$60
Rigel Pharmaceuticals, Inc.3$55
Myriad Genetic Laboratories, Inc.3$54
AbbVie2$52
EMD Serono, Inc.2$45
Springworks Therapeutics, Inc.2$43
Amneal Pharmaceuticals LLC2$43
Acrotech Biopharma Inc.2$39
Coherus Oncology, Inc.2$37
Sirtex Medical Inc2$35
Astellas Pharma US Inc1$34
EUSA Pharma (US) LLC2$29
Exelixis Inc.1$25
Syndax Pharmaceuticals, Inc.1$24
Geron Corporation1$24
Sun Pharmaceutical Industries Inc.1$24
Chiesi USA, Inc.1$23
Taiho Oncology, Inc.1$22
Iovance Biotherapeutics, Inc.1$21
Progenics Pharmaceuticals, Inc.1$21
Organon1$20
Partner Therapeutics, Inc.1$20
Clovis Oncology, Inc.1$18

How this compares

$12,398 in reported general payments places this provider in the 55th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$3,097,137
Medicare patients
282
Services billed
170,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib19$370,645
Tamsulosin Hcl13$269
Omeprazole12$177
Hydroxyurea13$172
Ciprofloxacin Hcl14$113
Azithromycin14$38

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →